A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).

Official Title
-----------------
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase II Study to Evaluate the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Conditions
-----------------
Chronic Hepatitis B

Intervention / Treatment
-----------------
* Drug: HRS9950 tablets
* Drug: HRS9950 tablets
* Drug: HRS9950 placebo tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet the body mass index standard among 18.0 to 30 kg/m2;； Chronic hepatitis B defined as HBV infection documented for at least 6 months prior to screening; Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation; On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 12 weeks before randomization; Need to take effective contraceptive measures； Volunteer to sign an informed consent. Exclusion Criteria: History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic hepatitis B that may affect the evaluation of the study; With autoimmune disease; With poorly-controlled diabetes, thyroid disease requiring clinical intervention, clinically significant thyroid dysfunction, neurological or psychiatric disorder, severe lung disease, chronic renal disease or retinopathy; History of solid organ transplantation or hematopoietic stem cell transplantation; Poorly-controlled hypertension, clinically significant and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases; Malignant tumors were diagnosed within 5 years prior to randomization； Infection requiring intervention within 4 weeks prior to randomization; Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results; Laboratory tests during the screening period were obviously abnormal; Prolonged ECG QTc interval (male > 450ms, female > 470ms) or other clinically significant abnormal results that may pose significant safety risks to subjects during the screening period; History of drug use, alcohol or drug abuse in the 12 months prior to randomization; Participated in clinical study of other drugs (received experimental drugs); Pregnant or nursing women; Allergic to a drug ingredient or component; Other reasons for ineligibility as judged by the investigators.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment group A: HRS9950 tablets (Low dose)<br> | Drug: HRS9950 tablets<br>* HRS9950 tablets, oral, once a week, low dose<br>|
| Experimental: Treatment group B: HRS9950 tablets (High dose)<br> | Drug: HRS9950 tablets<br>* HRS9950 tablets, oral, once a week, high dose<br>|
| Placebo Comparator: Placebo Comparator: Treatment group C<br> | Drug: HRS9950 placebo tablets<br>* HRS9950 placebo tablets, oral, once a week.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in mean log10 serum hepatitis B surface antigen levels from baseline to week 24 |  | Week 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes from baseline in mean log10 serum hepatitis B surface antigen levels |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with at least one log10 decline from baseline in serum hepatitis B surface antigen |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with serum hepatitis B surface antigen loss |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with serum hepatitis B surface antigen seroconversion |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with hepatitis B e-antigen loss |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with serum hepatitis B e-antigen seroconversion |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with virologic breakthrough |  | Pre-specified time points up to 48 weeks | 
| Proportion of subjects with drug resistance |  | Pre-specified time points up to 48 weeks |